YTD over 50% and churning out results. Whether too much was already priced in should become clear this afternoon.
July–September 2026 highlights
- Net sales were EUR 542.2 million (EUR 423.2 million in 7–9/2025)
- Operating profit was EUR 209.9 (121.0) million
- Basic earnings per share were EUR 1.19 (0.68)
- Cash flow from operating activities per share was EUR 0.68 (0.55)
- Phase 1 initiated with the ODM-216 molecule, Orion’s first investigational biologic to advance into clinical development
- Interim results from the Phase 3 DASL-HiCaP study presented at the ESMO 2026 Congress
- Changes in Orion Group’s Executive Management Board effective January 1, 2027
January–September 2026 highlights
- Net sales were EUR 1,481.5 million (EUR 1,194.2 million in 1–9/2025)
- Operating profit was EUR 501.2 (303.5) million
- Basic earnings per share were EUR 2.83 (1.71)
- Cash flow from operating activities per share was EUR 2.89 (1.67).
- The full-year 2026 outlook was upgraded after the reporting period in October: Net sales are estimated to be EUR 2,070–2,140 million. Operating profit is estimated to be EUR 730–790 million.
At least the algos found some weakness, as the share price dipped from about +2% → -2%